CRC Research Update — August 15, 2026
Today's colorectal cancer research highlights
Curated CRC research — accessible, accurate, actionable
The CRC Digest
Saturday, August 15, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
SCREENING
Multitarget stool DNA test shows promise over standard FIT screeningA systematic review found that multitarget stool DNA (mt-sDNA) testing emerged as a promising alternative to faecal immunochemical test (FIT) for detecting colorectal neoplasms, particularly given FIT's low sensitivity for advanced adenomas. (Cancer Epidemiology)
-
TREATMENT
Trifluridine/tipiracil outcomes examined in patients 75 and olderA single-center retrospective study compared relative dose intensity, toxicity, and survival between trifluridine/tipiracil (FTD/TPI) monotherapy and FTD/TPI plus bevacizumab in older patients with metastatic colorectal cancer, examining the relationship between dose intensity and overall survival. (Journal of Gastrointestinal Cancer)
-
RESEARCH
New gene circuit platform targets multiple KRAS mutations in preclinical modelsResearchers developed a platform that enables in vivo self-assembly of small extracellular vesicles encapsulating KRAS-specific siRNAs for broad targeting of KRAS mutants, showing activity in orthotopic models of KRAS G12D-, G12V-, and G13D-driven colorectal cancer. (Journal of Controlled Release)
-
TRIAL DATA
Adjuvant chemotherapy benefits occur early, not in late recurrencesA systematic review of phase III randomized controlled trials for gastrointestinal malignancies including colorectal cancer found that recurrence-free survival improvements were driven by early divergences during active chemotherapy, while late recurrences were not influenced by adjuvant therapy. (Journal of Surgical Research)
Research continues to advance our understanding of screening, treatment, and the molecular landscape of colorectal cancer across diverse populations and age groups.
Get CRC research intelligence delivered weekly — free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Every topic in this briefing has a live research dossier — trajectory and evidence — at Signal Bureau.
Got this from a colleague? Subscribe here — we only ever add readers who sign themselves up.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe — honored promptly, no login required. · Privacy policy · Manage or delete your data